Local/regional recurrence following surgery for early-stage lung cancer: A 10-year experience with 975 patients

Kelsey, Christopher R.; Boyd, Jessamy A.; Hubbs, Jessica L.; Hollis, Donna; Crawford, J.; Ready, Neal; D'Amcio, T. A.; Harpole, David H.; Garst, Jennifer; Marks, Lawrence B.

doi:10.1200/jco.2008.26.15_suppl.7542

Cited by 76 publications

(93 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Operation type, T stage, LVI and visceral pleural invasion were also related with DFS in our study but we didn't report recurrence pattern as local or distant. Total recurrence rate was 43.7% similar to their study (Kelsey et al, 2009). Cushodio et al (2008 analyzed the platin-taxan combination as adjuvant chemotherapy in 41 NSCLC patients with stage IB, II or stage IIIA (Cushodio et al, 2008).…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

Prognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences

Ustaalioğlu

Ünal²,

Turan³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 71%

“…Even patients are diagnosed in early stage, recurrence rates are high (Kelsey et al, 2009). 5-year OS rates are 73-25% for stage IA through stage IIIA (Sangha et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences

Ustaalioğlu

Ünal²,

Turan³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The majority of solid tumors are composed of a heterogeneous population including cells characterized by capacity for differentiation, self-renewal and resistance to chemotherapy, and radiotherapy (23,24). Although ~20% of patients with NSCLC exhibited surgically-correctable tumors at presentation, the recurrence rates following surgery remain high at 30-50% (25). This indicates that there is minimal residual disease, which contains a population that possesses a high proliferative potential and self-renewal capacity.…”

Section: Discussionmentioning

confidence: 99%

CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) accounts for >85% of incidences of lung cancer, for which the predicted 5-year survival rates are low and recurrence rates remain high. Although it has been reported that the patients with SCLC cells that possess the cluster of differentiation (CD) 117 marker exhibited poor prognosis and poor response to chemotherapy, no studies concerning the association of CD117 expression with prognosis of the patients with NSCLC have been reported. An in vitro study reportedly revealed that CD117-positive cell populations in NSCLC cell lines exhibited cancer stem cell (CSC) phenotypes including self-renewal and chemoresistance. Therefore, the present study hypothesized that if CD117-positive cells are CSC-like cells, CD117 positivity may be associated with the prognosis of patients with NSCLC. To confirm this hypothesis, the association between CD117 expression in patients with NSCLC and clinicopathological characteristics was investigated. CD177 expression was examined by immunohistochemistry in 99 patients with NSCLC who underwent curative surgical resection. Tumor samples in the present study included 73 samples of adenocarcinoma and 26 of squamous carcinoma. The associations of CD177 expression with clinicopathological features and prognosis were examined. The lymph node metastasis and rates of recurrence were significantly associated with overall survival rates through multivariate analysis (P<0.001 and P<0.001), respectively. A Kaplan-Meier analysis for relapse-free survival and the log-rank test revealed that the patients with CD117-positive cell populations exhibited shorter relapse-free survival rates compared with patients whose cells were CD117-negative (P=0.014). The multivariate analysis demonstrated that venous invasion, pathological stage, and CD117 expression were independent prognostic parameters for relapse-free survival in patients with NSCLC (P=0.001, P=0.001 and P=0.002), respectively. In conclusion, these data suggest that CD117 expression in NSCLC may serve as a useful marker for predicting the prognosis of patients with NSCLC.

show abstract

“…The risk of recurrence without ACT was derived from a study by Pepek et al, which reported the 5-year risk of cancer recurrence by stage (i.e., IA, IB, IIA, and IIB) [25]. Other studies were excluded because they did not report the results by stage at the level of granularity needed [26][27][28][29]. The risk of death after experiencing a cancer recurrence was pooled from two studies [30,31].…”

Section: Literature-derived Inputsmentioning

confidence: 99%

Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer

et al. 2015

View full text Add to dashboard Cite

Background. A prognostic test was developed to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC) adenocarcinomas.The objective of this study was to compare the cost-utility of the prognostic test to the current standard of care (SoC) in patients with early-stage NSCLC. Materials and Methods. Lifetime costs (2014 U.S. dollars) and effectiveness (quality-adjusted life-years [QALYs]) of ACT treatment decisions were examined using a Markov microsimulation model from a U.S. third-party payer perspective. Cancer stage distribution and probability of receiving ACT with the SoC were based on data from an academic cancer center. The probability of receiving ACT with the prognostic test was estimated from a physician survey. Risk classification was based on the 5-year predicted NSCLC-related mortality. Treatment benefit with ACT was based on the prognostic score. Discounting at a 3% annual rate was applied to costs and

show abstract

Local/regional recurrence following surgery for early-stage lung cancer: A 10-year experience with 975 patients

Cited by 76 publications

References 0 publications

Prognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences

Prognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences

CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer

Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About